Novo Nordisk's weight loss drugs, such as Wegovy and Ozempic, might be associated with significant stomach risks, according to a study.

 Novo Nordisk's weight loss drugs, such as Wegovy and Ozempic, might be associated with significant stomach risks, according to a study.

A recent study published in JAMA has raised concerns regarding the potential risks associated with popular weight loss and diabetes drugs such as Novo Nordisk A/S's NVO (+2.62% + Free Alerts), Wegovy (semaglutide), Ozempic (semaglutide), and Saxenda (liraglutide).

The study suggests that these drugs, known as GLP-1s, may be associated with three rare but severe stomach conditions in non-diabetic patients.

In the study, researchers identified stomach paralysis, bowel obstruction, and pancreatitis as the conditions linked to the use of these drugs. Notably, stomach paralysis, which can lead to persistent vomiting, is currently not listed as a warning on the drug labels.

The focus of the study was semaglutide, the active ingredient in Wegovy and Ozempic, which was compared to another weight loss treatment called bupropion-naltrexone.

By analyzing health insurance claim records for approximately 16 million U.S. patients, the study findings revealed that GLP-1s presented a significantly higher risk of pancreatitis, bowel obstruction, and stomach paralysis compared to bupropion-naltrexone.

The researchers specifically examined individuals with a recent history of obesity who had been prescribed semaglutide or liraglutide between 2006 and 2020. They intentionally excluded individuals with diabetes or those prescribed any other diabetes medication.

As a result of reported blocked intestines following the use of Novo Nordisk's Ozempic, the FDA has updated its labeling to include warnings.

Price Action: NVO shares are up 0.38% at $90.32 during the premarket session on the last check Friday.

...............................Read More Here................................